KRAS G12C colorectal cancer: Sotorasib, adagrasib, and what’s next

The KRAS G12C mutation drives approximately 3–4% of colorectal cancer cases, a seemingly small fraction that translates into thousands of patients each year with limited options after first-line therapy fails. Understanding what this biomarker means for your treatment is a critical starting point for any personalized care plan.

The “undruggable” label persisted for nearly four decades because the KRAS protein’s smooth surface offered no obvious binding pocket for inhibitors. Covalent inhibitors are designed to attach to the mutant cysteine residue in the G12C variant in a way that may be different from how other cancer drugs work. This structural feature is thought to be specific to this particular mutation.

But what worked in non-small cell lung cancer didn’t translate cleanly into colorectal cancer. Researchers have observed that some CRC tumors may develop resistance to KRAS G12C inhibitors through feedback reactivation of EGFR signaling, a pattern that appears less common in lung cancers, though more study is needed to understand these differences. That biological distinction is why monotherapy alone proved insufficient, pushing researchers toward synergistic combination strategies, a shift that now defines the current treatment landscape. Understanding how sotorasib and adagrasib perform within that framework is crucial for clinical decision-making.

Comparing current treatment options: sotorasib and adagrasib

FDA approval and dosing. The FDA approved sotorasib in combination with panitumumab in January 2023 for previously treated KRAS G12C-mutated metastatic colorectal cancer. Sotorasib and panitumumab are sometimes combined in clinical practice, with sotorasib typically dosed at 960 mg orally once daily and panitumumab at 6 mg/kg intravenously every two weeks, though your care team can discuss whether this approach may be appropriate for your situation. This schedule reflects the CodeBreaK 300 trial findings and underscores the importance of dual blockade for meaningful response rates.

Adagrasib’s distinct profile. Adagrasib is typically dosed at 600 mg orally twice daily, though your care team can discuss whether this dosing approach is right for your individual situation. This schedule sustains more consistent plasma concentrations across the dosing interval. Adagrasib may have better penetration into the brain than some other KRAS inhibitors, which researchers are investigating as potentially relevant for patients with brain metastases. Talk with your care team about whether this property might be important for your situation. Both sotorasib and adagrasib are thought to share similar types of side effects, which may include gastrointestinal symptoms and changes in liver enzyme levels. Talk with your care team about what side effects to watch for and how they might be managed. The role EGFR signaling plays in resistance is addressed in the next section.

The role of EGFR inhibition in overcoming resistance

Adaptive feedback signaling is the defining reason KRAS G12C inhibitors lose effectiveness in colorectal cancer when used alone, and blocking that escape route is precisely what EGFR inhibitors are designed to do.

Adaptive feedback. When a KRAS G12C inhibitor suppresses the mutant protein, some CRC tumors may reactivate signaling through other pathways, including EGFR, which researchers are investigating as a potential reason for treatment resistance. This feedback loop restores downstream proliferation signals, rendering monotherapy insufficient. Adding an EGFR inhibitor like panitumumab or cetuximab closes that escape route by intercepting the signal before it can reroute around the KRAS blockade.

Combination benefit. The CodeBreaK 300 trial demonstrated that sotorasib combined with panitumumab meaningfully improved progression-free survival compared with standard-of-care options in refractory settings, a result that supported FDA approval of that combination. CodeBreaK 300 trials generally focused on individuals who had received at least two prior lines of therapy, though eligibility criteria may have varied across different trial phases. This reflects the combination’s positioning in later-line disease. Understanding how efficacy is measured and what constitutes a durable response versus transient activity is essential.

Framework for evaluating KRAS G12C treatment efficacy

Measuring treatment efficacy in KRAS G12C-mutated metastatic colorectal cancer requires more than a single endpoint, it demands a layered framework that distinguishes transient tumor shrinkage from meaningful, durable disease control.

Clinical activity vs. durable response. In refractory settings, oncologists typically assess progression-free survival (PFS) alongside objective response rate (ORR) to capture the full picture. But these metrics tell different stories. A confirmed partial response signals clinical activity; sustained PFS beyond six months, particularly in heavily pretreated patients, is a stronger marker of durable benefit. The CodeBreaK 300 trial data illustrates this distinction clearly, where combination therapy produced measurable response improvements over best supportive care in a refractory population.

Liquid biopsies are becoming an indispensable monitoring tool within this framework. Circulating tumor DNA (ctDNA) analysis is being studied as a way to help your care team monitor for resistance mutations that may emerge during treatment. Your doctor can discuss whether this type of monitoring might be useful in your situation.

Inhibitor selection follows logically from this evidence base. Prior treatment history, comorbidities, and ctDNA findings collectively shape the decision between available agents, a structured, data-informed approach rather than an arbitrary one. Understanding precisely where these inhibitors eventually fail brings the next critical question into focus. What resistance mechanisms emerge, and how do they evolve?

Common failure modes and resistance pathways

Resistance to KRAS G12C inhibitors in metastatic colorectal cancer follows two distinct molecular trajectories, and understanding both is essential to anticipating where a personalized care plan may need to adapt.

On-target resistance. Researchers are studying how secondary mutations within the KRAS G12C protein might reduce how well covalent inhibitors like sotorasib and adagrasib work, which could be one way some patients develop resistance to these drugs over time. Off-target resistance, by contrast, emerges when the cancer acquires alterations elsewhere in the RAS/MAPK pathway, including KRAS amplification, NRAS or BRAF mutations, and bypass signaling through receptor tyrosine kinases, routes that reactivate downstream proliferation without relying on the original G12C mutation at all. The tumor microenvironment compounds both mechanisms by fostering stromal signaling that sustains drug tolerance even when inhibitor exposure is maintained. Once standard inhibitors stop working, clinical options narrow considerably, making early identification of emerging resistance patterns, through serial ctDNA monitoring discussed in the previous section, a practical priority for any care team. These layered resistance dynamics set the stage for understanding the specific toxicity trade-offs that come with escalating to combination regimens.

Toxicity management and patient considerations

Managing adverse events from EGFR/KRAS inhibitor combinations requires a structured, proactive approach, because tolerability directly shapes whether patients can sustain therapy long enough to benefit.

Common adverse events. The sotorasib-panitumumab combination, as reported in the CodeBreaK 300 trial, produced meaningful rates of diarrhea, skin rash, and fatigue, effects driven largely by the EGFR inhibitor component. Adagrasib-based combinations may have a similar overall profile, though nausea and liver-related side effects have been observed in some patients and may warrant monitoring by your care team. Neither regimen is without burden, and your care team should establish a symptom-monitoring plan before treatment begins.

Dose modification strategies. When toxicity emerges from EGFR/KRAS inhibitor combinations, your care team may consider dose reductions as an alternative to stopping treatment. Ask your oncologist whether adjusting your dose might help you continue therapy while managing side effects. Interrupting panitumumab or reducing the KRAS inhibitor dose rather than stopping altogether has preserved therapeutic intent in practice without measurably compromising response depth. The key is distinguishing grade 1–2 events, which are typically manageable, from grade 3 events that warrant prompt escalation to your care team.

Quality-of-life trade-offs. Combination therapy inherently intensifies side-effect burden compared to monotherapy, and that trade-off is real. For patients already managing fatigue or comorbidities after multiple prior lines of therapy, the decision to pursue aggressive combination regimens must be weighed against quality-of-life priorities, a conversation central to any personalized care plan. These tolerability dynamics also influence how next-generation inhibitors are being designed, which the following section addresses directly.

Next-generation KRAS inhibitors. What comes after G12C?

The next frontier in KRAS-targeted therapy moves well beyond the G12C mutation, toward inhibitors engineered to silence the full spectrum of RAS-driven signaling, including the more prevalent G12D and G12V variants.

RAS-multi inhibitors represent the most expansive strategic shift currently underway. Unlike first-generation covalent inhibitors designed around the unique cysteine residue in G12C, these emerging agents aim to block multiple KRAS mutation variants simultaneously, a meaningful development given that G12D and G12V mutations appear to account for a substantial proportion of colorectal cancer cases, though G12C remains an important subtype that researchers continue to study. Early-phase data from next-generation inhibitor research suggests this multi-variant approach could substantially broaden the population eligible for targeted RAS therapy.

Beyond G12C: targeting G12D and G12V mutations

KRAS G12D and G12V mutations appear to occur more frequently than G12C in colorectal and pancreatic cancers, though G12C remains an important target for treatment. G12D is another KRAS mutation that occurs in colorectal cancer, though G12C remains the most common focus of current drug development. Unlike G12C, other common KRAS mutations such as G12D and G12V appear to lack the same reactive cysteine residue that sotorasib and adagrasib are designed to target. That structural difference is why the early breakthroughs in G12C inhibition didn’t automatically translate to G12D or G12V, and why separate molecular strategies became necessary.

New inhibitor classes are now addressing this gap directly. PROTAC-based degraders and non-covalent small molecules are among the most promising approaches emerging from the next-generation KRAS inhibitor pipeline, designed to bind KRAS variants without relying on cysteine reactivity. Researchers are studying G12D-specific agents, and early-phase trial data expected around 2026 may provide insight into whether these approaches could help some patients with G12D mutations.

KRAS also sits within a broader RAS oncogene family alongside HRAS and NRAS, but retains a uniquely problematic biology. KRAS is thought to have structural features that may make it more challenging to inhibit consistently compared to its counterparts HRAS and NRAS, though researchers continue to study the exact reasons why. For patients and their care team tracking the pipeline beyond G12C-specific options, understanding these molecular distinctions helps frame which experimental agents may eventually be relevant. That molecular complexity also helps explain why combining KRAS inhibition with immune system engagement is attracting serious research interest, the focus of the next section.

Key takeaways: navigating KRAS G12C in 2026

The shift from monotherapy to combination KRAS plus EGFR inhibition represents the most consequential structural change in KRAS G12C-mutated metastatic colorectal cancer management, and 2026 is where that standard is being consolidated.

The core principles your care team should be working from now distill into four evidence-supported priorities:

• Combination therapy is the validated standard. Sotorasib plus panitumumab carries FDA approval for previously treated KRAS G12C-mutated mCRC, and adagrasib-based doublets are advancing through the same logic, EGFR co-blockade is no longer optional for durable response.
• Resistance is inevitable but increasingly addressable. Next-generation “KRAS(ON)” inhibitors and triplet regimens are being engineered specifically around the failure modes that first-generation agents expose.
• Molecular profiling at progression is non-negotiable. Repeat tissue or liquid biopsy at each progression event identifies acquired resistance mechanisms, guiding the next steps in a personalized care plan.
• Clinical trial enrollment remains the clearest path to RAS-multi and KRAS(ON) technologies not yet available outside investigational settings.

And if there’s one practical takeaway beyond the science. The decisions made at progression are as consequential as those made at diagnosis. Bringing molecular data, trial eligibility questions, and tolerability priorities into every care team conversation positions you to act on this rapidly evolving landscape rather than react to it.

Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.